Literature DB >> 28052224

Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs.

Anastasia Khvorova1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28052224     DOI： 10.1056/NEJMp1614154

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  31 in total

1.  Clinical Cancer Nanomedicine.

Authors:  Joy Wolfram; Mauro Ferrari
Journal:  Nano Today       Date:  2019-03-06       Impact factor: 20.722

Review 2.  The chemical evolution of oligonucleotide therapies of clinical utility.

Authors:  Anastasia Khvorova; Jonathan K Watts
Journal:  Nat Biotechnol       Date:  2017-02-27       Impact factor: 54.908

3.  The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo.

Authors:  Annabelle Biscans; Andrew Coles; Dimas Echeverria; Anastasia Khvorova
Journal:  J Control Release       Date:  2019-03-30       Impact factor: 9.776

4.  Therapeutic oligonucleotides in cardiovascular and metabolic diseases: insights for the internist.

Authors:  Domenico Girelli; Fabiana Busti; Giacomo Marchi; Nicola Martinelli; Oliviero Olivieri
Journal:  Intern Emerg Med       Date:  2018-03-01       Impact factor: 3.397

Review 5.  Improving siRNA Delivery In Vivo Through Lipid Conjugation.

Authors:  Maire F Osborn; Anastasia Khvorova
Journal:  Nucleic Acid Ther       Date:  2018-05-10       Impact factor: 5.486

6.  Non-viral Delivery of Zinc Finger Nuclease mRNA Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets.

Authors:  Anthony Conway; Matthew Mendel; Kenneth Kim; Kyle McGovern; Alisa Boyko; Lei Zhang; Jeffrey C Miller; Russell C DeKelver; David E Paschon; Barbara L Mui; Paulo J C Lin; Ying K Tam; Chris Barbosa; Tom Redelmeier; Michael C Holmes; Gary Lee
Journal:  Mol Ther       Date:  2019-03-07       Impact factor: 11.454

Review 7.  Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives.

Authors:  Wolfgang Poller; Stefanie Dimmeler; Stephane Heymans; Tanja Zeller; Jan Haas; Mahir Karakas; David-Manuel Leistner; Philipp Jakob; Shinichi Nakagawa; Stefan Blankenberg; Stefan Engelhardt; Thomas Thum; Christian Weber; Benjamin Meder; Roger Hajjar; Ulf Landmesser
Journal:  Eur Heart J       Date:  2018-08-01       Impact factor: 29.983

8.  Pharmacokinetic Profiling of Conjugated Therapeutic Oligonucleotides: A High-Throughput Method Based Upon Serial Blood Microsampling Coupled to Peptide Nucleic Acid Hybridization Assay.

Authors:  Bruno M D C Godinho; James W Gilbert; Reka A Haraszti; Andrew H Coles; Annabelle Biscans; Loic Roux; Mehran Nikan; Dimas Echeverria; Matthew Hassler; Anastasia Khvorova
Journal:  Nucleic Acid Ther       Date:  2017-10-12       Impact factor: 5.486

9.  2'-O-Methylation can increase the abundance and lifetime of alternative RNA conformational states.

Authors:  Hala Abou Assi; Atul K Rangadurai; Honglue Shi; Bei Liu; Mary C Clay; Kevin Erharter; Christoph Kreutz; Christopher L Holley; Hashim M Al-Hashimi
Journal:  Nucleic Acids Res       Date:  2020-12-02       Impact factor: 16.971

Review 10.  The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?

Authors:  Marcio H Miname; Viviane Z Rocha; Raul D Santos
Journal:  Curr Atheroscler Rep       Date:  2021-06-19       Impact factor: 5.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.